Talk to the Institute
Published mark

ArriVent BioPharma, Inc.

NASDAQ: AVBP. ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c
SEC CIK
0001868279
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 16, 2026
Newest evidence
Apr 28, 2025
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Not published
Chair
Not published
Independent
6 / 88 directors published
Published claims
212 distinct sources
Evidence records
30 pinned
Source conflicts
0None open

Built from 2 distinct sources and 3 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

DIRECTOR APPOINTED

Merdad Parsey, M.D., Ph.D. seat on ArriVent BioPharma, Inc., effective 2025-01-01.

EffectiveEffective Jan 1, 2025E2

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Board of directors

Evidence

8 directors published. 6 of 8 with a published determination are independent.

DirectorStatusSinceCommitteesClaim
Carl L. Gordon, Ph.D., CFAIndependent2022None publishedSource reportedE2
Chris W. NoletIndependent2023Audit, chairAudit · Chair; Nominating and GovernanceNominating and GovernanceSource reportedE2
James Healy, M.D., Ph.D.Independent2023None publishedSource reportedE2
John Hohneker, M.D.Independent2024None publishedSource reportedE2
Kristine PetersonIndependent2024AuditAudit; Compensation · ChairCompensation, chairSource reportedE2
Merdad Parsey, M.D., Ph.D.Independent2025None publishedSource reportedE2
Stuart Lutzker, M.D., Ph.D.Not independent2021None publishedSource reportedE2
Zarath Summers, Ph.D.Not independent2021None publishedSource reportedE2

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
AuditChris W. NoletChris W. Nolet, Kristine PetersonNot described in the published record
Audit · Chair; Nominating and GovernanceNot publishedChris W. NoletNot described in the published record
Audit; Compensation · ChairNot publishedKristine PetersonNot described in the published record
CompensationKristine PetersonKristine PetersonNot described in the published record
Nominating and GovernanceNot publishedChris W. NoletNot described in the published record
Committee RecordAudit: Chair Chris W. Nolet; Members Chris W. Nolet (Chair); Kristine Peterson
Source reportedE3
company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c:committee_record:15
Committee AppointmentChris W. Nolet: chair, Audit
Source reportedE3
company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c:committee_appointment:16
Committee AppointmentKristine Peterson: member, Audit
Source reportedE3
company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c:committee_appointment:17
Committee RecordCompensation: Chair Kristine Peterson; Members Kristine Peterson (Chair)
Source reportedE3
company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c:committee_record:18
Committee AppointmentKristine Peterson: chair, Compensation
Source reportedE3
company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c:committee_appointment:19
Committee RecordNominating and Governance: Chair not stated; Members Chris W. Nolet
Source reportedE3
company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c:committee_record:20
Committee AppointmentChris W. Nolet: member, Nominating and Governance
Source reportedE3
company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c:committee_appointment:21

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingAVBP (NASDAQ)
Source reportedE1
company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c:security_listing:22
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 16, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameArriVent BioPharma, Inc.
Source reportedE1
company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c:entity_status:3
Published FactHealthcare
Source reportedE1
company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c:published_fact:5
Published FactBiotechnology
Source reportedE1
company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c:published_fact:6

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • LeadershipNot reviewed. Executive leadership carries operating authority.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
3 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 16, 2026. Cited by 6 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    ArriVent BioPharma, Inc. DEF 14A 2025-04-28
    sec proxy. Published Apr 28, 2025. Retrieved Apr 24, 2026. Cited by 8 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    Audit
    board_seats. board seats. Cited by 7 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 16, 2026
  • Merdad Parsey, M.D., Ph.D. seat on ArriVent BioPharma, Inc., effective 2025-01-01.
  • John Hohneker, M.D. seat on ArriVent BioPharma, Inc., effective 2024-01-01.
  • Kristine Peterson seat on ArriVent BioPharma, Inc., effective 2024-01-01.
  • Audit; Compensation · Chair committee of ArriVent BioPharma, Inc., effective 2024-01-01.
  • Kristine Peterson member of Audit; Compensation · Chair, effective 2024-01-01.
  • Chris W. Nolet seat on ArriVent BioPharma, Inc., effective 2023-01-01.
  • James Healy, M.D., Ph.D. seat on ArriVent BioPharma, Inc., effective 2023-01-01.
  • Audit · Chair; Nominating and Governance committee of ArriVent BioPharma, Inc., effective 2023-01-01.
  • Chris W. Nolet member of Audit · Chair; Nominating and Governance, effective 2023-01-01.
  • Carl L. Gordon, Ph.D., CFA seat on ArriVent BioPharma, Inc., effective 2022-01-01.
  • Stuart Lutzker, M.D., Ph.D. seat on ArriVent BioPharma, Inc., effective 2021-01-01.
  • Zarath Summers, Ph.D. seat on ArriVent BioPharma, Inc., effective 2021-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/arrivent-biopharma-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership0
  4. Board8
  5. Committees5
  6. Control and voting0
  7. Authority to act3
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims5
  15. Coverage gaps18
  16. Linked people8
  17. Subject and corrections6
  18. Evidence3
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c
  • Cite this recordArriVent BioPharma, Inc.
  • Copy canonical URLregistry.alpha.ac/companies/arrivent-biopharma-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    ArriVent BioPharma, Inc.Company
  • Carl L. Gordon, Ph.D., CFAPerson
  • Chris W. NoletPerson
  • James Healy, M.D., Ph.D.Person
  • John Hohneker, M.D.Person
  • Kristine PetersonPerson
  • Merdad Parsey, M.D., Ph.D.Person
  • Stuart Lutzker, M.D., Ph.D.Person
  • Zarath Summers, Ph.D.Person
  • Sections
    OverviewArriVent BioPharma, Inc.
  • MonitoringArriVent BioPharma, Inc.
  • LeadershipArriVent BioPharma, Inc.
  • BoardArriVent BioPharma, Inc.
  • CommitteesArriVent BioPharma, Inc.
  • Control and votingArriVent BioPharma, Inc.
  • Authority to actArriVent BioPharma, Inc.
  • FinancialsArriVent BioPharma, Inc.
  • GovernanceArriVent BioPharma, Inc.
  • RiskArriVent BioPharma, Inc.
  • AI oversightArriVent BioPharma, Inc.
  • LegalArriVent BioPharma, Inc.
  • CompensationArriVent BioPharma, Inc.
  • Other published claimsArriVent BioPharma, Inc.
  • Coverage gapsArriVent BioPharma, Inc.
  • Linked peopleArriVent BioPharma, Inc.
  • Subject and correctionsArriVent BioPharma, Inc.
  • EvidenceArriVent BioPharma, Inc.
  • Version historyArriVent BioPharma, Inc.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.